A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Inclusion Criteria:

Subjects who have relapsed or refractory MDS.

Subject enrolled in venetoclax monotherapy must have documented failure of prior therapy with a hypomethylating agent (HMA). HMA-failure is defined as:

Relapse after initial complete or partial response or hematological improvement after at least 4 cycles of azacitidine or at least 4 cycles of decitabine within the last 5 years, OR
Failure to achieve complete or partial response or hematological improvement after at least 4 cycles of azacitidine or at least 4 cycles of decitabine within the last 5 years
Subjects must have presence of < 20% bone marrow blasts per bone marrow biopsy/aspirate at screening.
Subject is not a candidate to undergo allogenic hematopoietic stem cell transplantation (HSCT).
Subject must have an Eastern Cooperative Oncology Group (ECOG) performance score of ≤2.
Subject must have adequate hematologic, renal, and hepatic function.

Exclusion Criteria:

Subject has received prior therapy with a BH3 mimetic.
Subject has MDS evolving from a pre-existing myeloproliferative neoplasm (MPN).
Subject has MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.
Subject has received allogeneic HSCT or solid organ transplantation.
Subject has received a live attenuated vaccine within 4 weeks prior to the first dose of study drug.
Subject is pregnant or breastfeeding.